Immunovant's Q1 Loss Narrower Than Expected, Pipeline in Focus
IMVT reports a narrower Q1 loss, as spotlight remains on IMVT-1402's broad clinical potential across multiple indications.
Immunovant Posts 34% R&D Jump in Q1
Immunovant ( NASDAQ:IMVT ) , a clinical-stage biotechnology company focused on therapies for autoimmune conditions, reported results for the quarter ended June 30, 2025, on August 11, 2025. Net loss per common share ( GAAP ) was $0.71 in Q1 FY2026.
All You Need to Know About Immunovant ( IMVT ) Rating Upgrade to Buy
Immunovant (IMVT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Wall Street Analysts See a 137.68% Upside in Immunovant ( IMVT ) : Can the Stock Really Move This High?
The mean of analysts' price targets for Immunovant (IMVT) points to a 137.7% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Avalo Therapeutics Announces Appointment of Rita Jain, M.D. to Board of Directors - Avalo Therapeutics ( NASDAQ:AVTX )
WAYNE, Pa., June 18, 2025 ( GLOBE NEWSWIRE ) -- Avalo Therapeutics, Inc. AVTX, a clinical stage biotechnology company focused on the treatment of immune dysregulation, today announced the appointment of Rita Jain, M.D. to its Board of Directors.
Immunovant ( IMVT ) Upgraded to Buy: What Does It Mean for the Stock?
Immunovant (IMVT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
IMVT Q4 Loss Narrower Than Expected, Stock Up, Pipeline in Focus
Immunovant stock rises on encouraging fourth-quarter fiscal 2025 results. It is on track to initiate 10 studies on IMVT-1402 across various autoimmune indications.
Charles Schwab To Rally Around 24%? Here Are 10 Top Analyst Forecasts For Tuesday - Comerica ( NYSE:CMA ) , Alumis ( NASDAQ:ALMS )
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. HC Wainwright & Co. cut Alumis Inc. ALMS price target from $15 to $14.
Immunovant Announces Next Phase of Growth with Roivant Including Changes to its Leadership Team and Additional Indications Sjögren's Disease ( SjD ) and Cutaneous Lupus Erythematosus ( CLE ) for IMVT-1402
NEW YORK, April 21, 2025 ( GLOBE NEWSWIRE ) -- Immunovant, Inc. ( Nasdaq: IMVT ) , a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today announced next phase of growth including changes to its leadership team and the expanded ...
Immunovant Announces Next Phase of Growth with Roivant Including Changes to its Leadership Team and Additional Indications Sjögren's Disease ( SjD ) and Cutaneous Lupus Erythematosus ( CLE ) for IMVT-1402
NEW YORK, April 21, 2025 ( GLOBE NEWSWIRE ) -- Immunovant, Inc. ( Nasdaq: IMVT ) , a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today announced next phase of growth including changes to its leadership team and the expanded ...
IMVT Unlikely to Pursue Batoclimab for MG & CIDP Despite Success
Immunovant's batoclimab shows strong efficacy in MG & CIDP, but shifts focus to the lead drug IMVT-1402 for these indications to induce deeper, lasting relief.
Immunovant Ditches Seeking FDA Approval For Batoclimab For Two Autoimmune Disorders Despite Positive Phase 3 Data - Immunovant ( NASDAQ:IMVT )
Batoclimab met the primary endpoint in a Phase 3 MG study, showing up to a 5.6-point MG-ADL improvement with 74% mean IgG reduction. Immunovant will not seek approval for batoclimab in MG or CIDP but plans registrational studies for IMVT-1402 in both conditions.
Immunovant Announces Positive Results for Batoclimab Myasthenia Gravis ( MG ) and Chronic Inflammatory Demyelinating Polyneuropathy ( CIDP ) Studies - Immunovant ( NASDAQ:IMVT )
Pivotal study in MG met primary endpoint of change from baseline in MG-ADL in AChR+ population at 12 weeks, with a 5.6 point improvement in the higher dose arm ( with 74% mean IgG reduction ) and a 4.7 point improvement in the lower dose arm ( with 64% mean IgG reduction )
Immunovant Announces Positive Results for Batoclimab Myasthenia Gravis ( MG ) and Chronic Inflammatory Demyelinating Polyneuropathy ( CIDP ) Studies
NEW YORK, March 19, 2025 ( GLOBE NEWSWIRE ) -- Immunovant, Inc. ( Nasdaq: IMVT ) , a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today reported topline results from its Phase 3 study of batoclimab in MG and initial results from Period ...
Roivant Announces Positive Results for Batoclimab Myasthenia Gravis ( MG ) and Chronic Inflammatory Demyelinating Polyneuropathy ( CIDP ) Studies
NEW YORK, March 19, 2025 ( GLOBE NEWSWIRE ) -- Immunovant, Inc. ( Nasdaq: IMVT ) , a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today reported topline results from its Phase 3 study of batoclimab in MG and initial results from Period ...
Immunovant to Host Investor Webcast at 8:00 AM ET on Wednesday, March 19 to Review Results from Batoclimab Myasthenia Gravis ( MG ) and Chronic Inflammatory Demyelinating Polyneuropathy ( CIDP ) Programs
NEW YORK, March 18, 2025 ( GLOBE NEWSWIRE ) -- Immunovant, Inc. ( Nasdaq: IMVT ) , a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today announced that it will host an investor webcast on Wednesday, March 19th at 8:00 a.m.
Immunovant to Host Investor Webcast at 8:00 AM ET on Wednesday, March 19 to Review Results from Batoclimab Myasthenia Gravis ( MG ) and Chronic Inflammatory Demyelinating Polyneuropathy ( CIDP ) Programs - Immunovant ( NASDAQ:IMVT )
NEW YORK, March 18, 2025 ( GLOBE NEWSWIRE ) -- Immunovant, Inc. IMVT, a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today announced that it will host an investor webcast on Wednesday, March 19th at 8:00 a.m.
Roivant to Host Investor Webcast at 8:00 AM ET on Wednesday, March 19 to Review Results from Batoclimab Myasthenia Gravis ( MG ) and Chronic Inflammatory Demyelinating Polyneuropathy ( CIDP ) Programs
NEW YORK, March 18, 2025 ( GLOBE NEWSWIRE ) -- Immunovant, Inc. ( Nasdaq: IMVT ) , a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today announced that it will host an investor webcast on Wednesday, March 19th at 8:00 a.m.
Roivant to Host Investor Webcast at 8:00 AM ET on Wednesday, March 19 to Review Results from Batoclimab Myasthenia Gravis ( MG ) and Chronic Inflammatory Demyelinating Polyneuropathy ( CIDP ) Programs - Immunovant ( NASDAQ:IMVT ) , Roivant Sciences ( NASDAQ:ROIV )
NEW YORK, March 18, 2025 ( GLOBE NEWSWIRE ) -- Immunovant, Inc. IMVT, a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today announced that it will host an investor webcast on Wednesday, March 19th at 8:00 a.m.
Incyte ( INCY ) Up 2.6% Since Last Earnings Report: Can It Continue?
Incyte (INCY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Immunovant ( IMVT ) Loses -15.47% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Immunovant (IMVT) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
IMVT Q3 Loss Wider Than Expected, Stock Down, Pipeline in Focus
Immunovant stock down on dismal third-quarter fiscal 2025 results. It is on track to initiate 10 studies on IMVT-1402 across various autoimmune indications.
Immunovant Reports Financial Results for the Quarter Ended December 31, 2024
NEW YORK, Feb. 06, 2025 ( GLOBE NEWSWIRE ) -- Immunovant, Inc. ( Nasdaq: IMVT ) , a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today reported financial results for its fiscal third quarter ended December 31, 2024.
Immunovant's Q2 Loss Wider Than Expected, Pipeline in Focus
IMVT reports dismal second-quarter fiscal 2025 results. It is on track to initiate several studies on IMVT-1402 across various autoimmune indications.
Immunovant Announces Oral Presentation of Late Breaking Abstract for Phase 2 Graves' Disease Clinical Data at the 2024 American Thyroid Association ( ATA ) Annual Meeting - Immunovant ( NASDAQ:IMVT )
NEW YORK, Oct. 29, 2024 ( GLOBE NEWSWIRE ) -- Immunovant, Inc.
Biotech Stock Roundup: TERN, SMMT Stocks Surge on Study Data, GSK's Vaccine Study Fails & More
Terns Pharmaceuticals and Summit Therapeutics are in the spotlight following positive updates on key candidates.
What the Options Market Tells Us About Immunovant - Immunovant ( NASDAQ:IMVT )
Whales with a lot of money to spend have taken a noticeably bullish stance on Immunovant. Looking at options history for Immunovant IMVT we detected 10 trades. If we consider the specifics of each trade, it is accurate to state that 70% of the investors opened trades with bullish expectations ...
Roivant Unveils New Pipeline Program Mosliciguat, A Potential First-In-Class and Best-In-Category Inhaled Once-Daily Soluble Guanylate Cyclase ( sGC ) Activator
BASEL, Switzerland and LONDON and NEW YORK, Sept. 10, 2024 ( GLOBE NEWSWIRE ) -- Roivant ( Nasdaq: ROIV ) today announced its previously undisclosed pipeline program mosliciguat, a potential first-in-class, inhaled, once-daily sGC activator with targeted delivery to the lungs via dry powder ...
Roivant Unveils New Pipeline Program Mosliciguat, A Potential First-In-Class and Best-In-Category Inhaled Once-Daily Soluble Guanylate Cyclase ( sGC ) Activator - Roivant Sciences ( NASDAQ:ROIV )
Mosliciguat, a potential first-in-class and best-in-category inhaled soluble Guanylate Cyclase ( sGC ) activator with targeted delivery to the lungs and once-daily administration, is being developed for pulmonary hypertension associated with interstitial lung disease ( PH-ILD ) , which affects ...
IMVT Stock Up on Upbeat Data From Graves' Disease Study of Batoclimab - Illumina ( NASDAQ:ILMN ) , Fulcrum Therapeutics ( NASDAQ:FULC )
Shares of Immunovant IMVT are rising in the pre-market hours on Sept. 9 after the company announced positive data from the mid-stage study of its investigational candidate, batoclimab, which is being developed for Graves' Disease.
What's Going In With Vivek Ramaswamy-Founded Roivant Sciences Stock On Monday? - Immunovant ( NASDAQ:IMVT ) , Roivant Sciences ( NASDAQ:ROIV )
Monday, Immunovant, Inc. IMVT reported results from the Phase 2a trial of batoclimab in Graves' Disease, an immune system condition that affects the thyroid gland. It causes the body to make too much thyroid hormone. Immunovant is a member of the Roivant Sciences Ltd. ROIV family of companies.
Top 2 Health Care Stocks That May Collapse This Quarter - Terns Pharma ( NASDAQ:TERN )
As of Sept. 9, 2024, two stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions. The RSI is a momentum indicator, which compares a stock's strength on days when prices go up to its strength on days when prices ...
IMVT Stock Up on Upbeat Data From Graves' Disease Study of Batoclimab
Immunovant stock rises on mid-stage study data of batoclimab for Graves' Disease, showing superior efficacy compared to anti-thyroid drug therapy options.
Immunovant Provides Update on Graves' Disease Development Program
NEW YORK, Sept. 09, 2024 ( GLOBE NEWSWIRE ) -- Immunovant, Inc. ( Nasdaq: IMVT ) , a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today reported positive results from the Phase 2a trial of batoclimab in Graves' Disease.
Why Is Immunovant ( IMVT ) Up 13.8% Since Last Earnings Report?
Immunovant (IMVT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Immunovant to Host Graves' Disease Program Update on September 9, 2024
Investor webcast on Monday, September 9th at 8:00 a.m. ET Investor webcast on Monday, September 9th at 8:00 a.m. ET ...
Immunovant to Host Graves' Disease Program Update on September 9, 2024
NEW YORK, Sept. 05, 2024 ( GLOBE NEWSWIRE ) -- Immunovant, Inc. IMVT, a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today announced that it will host an investor webcast on Monday, September 9th at 8:00 a.m.
Dianthus ( DNTH ) Gains 18% in the Past Month: Here's Why
Dianthus (DNTH) shares have rallied 18% in the past month on FDA clearance to initiate a phase II study on its lead candidate, DNTH103, to treat an autoimmune indication. Top-line data is expected in 2026.
Immunovant ( IMVT ) Down 1.6% Since Last Earnings Report: Can It Rebound?
Immunovant (IMVT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Immunovant ( IMVT ) Falls as Q4 Earnings Miss, Pipeline in Focus
Immunovant (IMVT) declines 5% on dismal fourth-quarter fiscal 2024 results. The company names IMVT-1402 as its new lead candidate to initiate several studies for autoimmune indications.
After Biohaven Kerfuffle, Immunovant Dives On A Surprise Delay
Immunovant Stock Dives On Surprise Shift To Earlier-Stage Drug Investor's Business Daily ...
Roivant Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2024, and Provides Business Update
BASEL, Switzerland and LONDON and NEW YORK, May 30, 2024 ( GLOBE NEWSWIRE ) -- Roivant ( Nasdaq: ROIV ) today reported its financial results for the fourth quarter and fiscal year ended March 31, 2024, and provided a business update.
Biohaven Stock Stumbles As Protein-Degrading Drug Falls Short Of Expectations In Early-Stage Study - Biohaven ( NYSE:BHVN )
Biohaven Ltd's BHVN shares are trading lower on Wednesday. The company reported new interim data from the ongoing Phase 1 study of BHV-1300, Biohaven's lead investigational drug, from its Molecular Degrader of Extracellular Proteins ( MoDE ) platform.
Heico Posts Upbeat Earnings, Joins Surmodics, Abercrombie & Fitch And Other Big Stocks Moving Higher On Wednesday - Heico ( NYSE:HEI )
U.S. stocks were lower, with the Dow Jones index falling more than 300 points on Wednesday. Shares of HEICO Corporation HEI rose sharply during Wednesday's session following a second-quarter earnings beat. Heico posted quarterly GAAP earnings of 88 cents per share, beating market estimates of 81 ...
Stocks With Rising Relative Strength: Immunovant
The Relative Strength ( RS ) Rating for Immunovant ( IMVT ) moved up into a new percentile Wednesday, as it got a lift from 67 to 72. X This exclusive rating from Investor's Business Daily measures price action with a 1 ( worst ) to 99 ( best ) score.
Wall Street Analysts Think Immunovant ( IMVT ) Could Surge 68.63%: Read This Before Placing a Bet
The average of price targets set by Wall Street analysts indicates a potential upside of 68.6% in Immunovant (IMVT). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Zacks Industry Outlook Highlights BioMarin, Blueprint Medicines, Immunovant, Kymera and Ligand
BioMarin, Blueprint Medicines, Immunovant, Kymera and Ligand have been highlighted in this Industry Outlook article.
5 Biotech Stocks Worth Adding to Your Portfolio in 2024
New drug approvals and pipeline progress are likely to help maintain the momentum for the Zacks Biomedical and Genetics industry. A strong portfolio and solid pipeline progress position BMRN, BPMC, IMVT, KYMR and LGND well amid volatility.
HanAll Biopharma Reports Q1 2024 Financial Results and Provides Business Update
• Delivered solid performance to start 2024, with record-breaking first quarter revenue of .
Here's Why You Should Add Immunovant ( IMVT ) to Your Portfolio
Immunovant's (IMVT) late-stage studies evaluating its lead candidate, batoclimab, for various autoimmune indications are progressing well. Several data readouts are expected in 2024 and 2025.
